Drug Profile
MM 310
Alternative Names: MM-310Latest Information Update: 11 Apr 2019
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer Merrimack Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Eph family receptor modulators; EphA2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Apr 2019 Discontinued - Phase-I for Solid tumours (Second-line therapy or greater) in USA (IV)
- 07 Nov 2018 Preliminary efficacy and safety data from a phase I trial in Solid tumours released by Merrimack Pharmaceuticals
- 23 Mar 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in USA (IV) (NCT03076372)